Pamiparib
Carcinosarcoma
Australia New Zealand Gynaecological Oncology GroupSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Carcinosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Blueprint Medicines Corporation | Phase 3 | BB |
Isocyclophosphamide GOG Foundation | Phase 3 | B |
Sirexatamab Leap Therapeutics, Inc. | Phase 2 | B |
Nivolumab Instituto do Cancer do Estado de São Paulo | Phase 2 | CCC |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Pamiparib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →